Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 39

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Prostate cancer

Not yet recruiting

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Universitaetsklinikum Essen AöR

Breast cancer metastatic

Not yet recruiting

Study of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Curie

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Breast neoplasm

Not yet recruiting

Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Centre Regional Lutte Contre Le Cancer

Endometriosis

Not yet recruiting

Study of cabergoline compared to dienogest and ethinylestradiol for reducing endometriosis symptoms and lesion size in women with confirmed endometriosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cabergoline
  • Sponsor:Hospital Clinico San Carlos

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Amsterdam UMC Stichting

Infertility female

Not yet recruiting

Study of Platelet-Rich Plasma and Growth Factors Given by Ovarian Injection to Women with Low Ovarian Reserve During IVF Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Platelet Concentrate
  • Sponsor:Ivi Alicante S.L.

Prostate cancer

Not yet recruiting

Evaluating Technetium-99m and Cyanine-5 PSMA Tracer-Guided Surgery for Patients with Prostate Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:99MTC-EUK-(SO3)CY5-MAS3
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Chronic prostatitis/chronic pelvic pain syndrome

Not yet recruiting

Study on Botulinum Toxin Type A for Adults with Chronic Pelvic Pain Syndrome (CPPS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Ospedale San Raffaele S.r.l.

Gastroenteropancreatic neuroendocrine tumour disease+5

Not yet recruiting

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Hospices Civils De Lyon

Prostate cancer

Not yet recruiting

Study on the Safety and Effectiveness of SpectraCure P18 System and Verteporfin for Treating Localized Prostate Cancer in Men

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:SpectraCure AB (publ)

Breast cancer+2

Not yet recruiting

Study on Everolimus and Exemestane for Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Orszagos Onkologiai Intezet

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.